Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2026-05-29 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于累计诉讼事项的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement (“公告”) by a listed company disclosing cumulative litigation and arbitration matters with detailed case lists and amounts. It provides updates on significant lawsuits and legal proceedings involving the company, matching the definition of a Legal Proceedings Report. Therefore, it should be classified as LTR.
2026-05-29 Chinese
关于申请借款重组的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for loan restructuring, detailing the loan amounts, guarantees, collateral, and the impact on the company. It includes information about board approval and the company's financial obligations related to guarantees. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is a formal announcement about financing activities, specifically loan restructuring and guarantees, which fits the category of Capital/Financing Update (CAP). The document length is 2405 characters, which is relatively short but contains substantive information about financing arrangements rather than just a notice or report publication announcement. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-02-13 Chinese
第九届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 广州市香雪制药股份有限公司, detailing the approval of a loan restructuring proposal. It includes meeting details, voting results, and authorization for signing related legal documents. There is no financial report, audit, or earnings data presented. The content focuses on board decisions and management authorization, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2026-02-13 Chinese
关于累计诉讼事项的公告
Legal Proceedings Report Classification · 95% confidence The document is a detailed announcement from 广州市香雪制药股份有限公司 regarding cumulative litigation matters involving the company and its subsidiaries over a twelve-month period. It includes extensive tables listing various lawsuits, arbitration cases, their progress, and involved amounts. The document references compliance with Shenzhen Stock Exchange listing rules and mentions that the company has disclosed major litigation matters in its 2024 annual report and 2025 semi-annual report. The content focuses on legal proceedings and their potential impact on the company, without presenting financial statements or management analysis. This matches the description of a Legal Proceedings Report, which covers updates on significant lawsuits and regulatory actions involving the company. The document is lengthy (over 14,000 characters) and contains substantive information about legal matters, not just an announcement or summary. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2026-02-08 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast (业绩预告) for the fiscal year 2025, issued by 广州市香雪制药股份有限公司. It provides estimated net profit figures, explanations for the expected losses, and notes that the data is preliminary and unaudited. It explicitly states that the final audited results will be disclosed in the 2025 Annual Report. The document is short (1087 characters) and serves as an announcement of expected financial results rather than a full financial report. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2025
2026-01-30 Chinese
关于XLS-103注射液获得药物临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the approval of clinical trial permits for a new drug injection (XLS-103). It details the drug's clinical trial approval, basic drug information, R&D status, market context, and risk warnings. The document is relatively short (2802 characters) and serves as a regulatory announcement about the clinical trial approval rather than a financial report or detailed data. It does not contain financial statements, earnings data, or management discussion. It is not a report publication announcement since it contains substantive information about the clinical trial approval. The content fits best under a Regulatory Filings (RNS) category as it is a regulatory announcement about drug trial approval and related disclosures.
2025-12-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.